Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 5;14(11):e1007431.
doi: 10.1371/journal.ppat.1007431. eCollection 2018 Nov.

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

Celia C LaBranche  1 , Andrew T McGuire  2 , Matthew D Gray  2 , Shay Behrens  1 , Peter D Kwong, Xuejun Chen  3 , Tongqing Zhou  3 , Quentin J Sattentau  4 , James Peacock  5 , Amanda Eaton  1 , Kelli Greene  1 , Hongmei Gao  1 , Haili Tang  1 , Lautaro G Perez  1 , Xuejun Chen, Kevin O Saunders  1 , Peter D Kwong  3 , John R Mascola  3 , Barton F Haynes  5 , Leonidas Stamatatos  2   6 , David C Montefiori  1
Affiliations

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

Celia C LaBranche et al. PLoS Pathog. .

Erratum in

Abstract

Broadly neutralizing antibody (bnAb) induction is a high priority for effective HIV-1 vaccination. VRC01-class bnAbs that target the CD4 binding site (CD4bs) of trimeric HIV-1 envelope (Env) glycoprotein spikes are particularly attractive to elicit because of their extraordinary breadth and potency of neutralization in vitro and their ability to protect against infection in animal models. Glycans bordering the CD4bs impede the binding of germline-reverted forms of VRC01-class bnAbs and therefore constitute a barrier to early events in initiating the correct antibody lineages. Deleting a subset of these glycans permits Env antigen binding but not virus neutralization, suggesting that additional barriers impede germline-reverted VRC01-class antibody binding to functional Env trimers. We investigated the requirements for functional Env trimer engagement of VRC01-class naïve B cell receptors by using virus neutralization and germline-reverted antibodies as surrogates for the interaction. Targeted deletion of a subset of N-glycans bordering the CD4bs, combined with Man5 enrichment of remaining N-linked glycans that are otherwise processed into larger complex-type glycans, rendered HIV-1 426c Env-pseudotyped virus (subtype C, transmitted/founder) highly susceptible to neutralization by near germline forms of VRC01-class bnAbs. Neither glycan modification alone rendered the virus susceptible to neutralization. The potency of neutralization in some cases rivaled the potency of mature VRC01 against wildtype viruses. Neutralization by the germline-reverted antibodies was abrogated by the known VRC01 resistance mutation, D279K. These findings improve our understanding of the restrictions imposed by glycans in eliciting VRC01-class bnAbs and enable a neutralization-based strategy to monitor vaccine-elicited early precursors of this class of bnAbs.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist

Figures

Fig 1
Fig 1. Complementarity of targeted glycan-deletion and Man5-enrichement for neutralization by germline-reverted VRC01.
Parental and glycan deletion mutants of 426c were produced as Env-pseudotyped viruses in 293T and 293S GnT1- cells and assayed for neutralization by mature and germline-reverted VRC01 in TZM-bl cells. The 426c glycan deletion mutants were SM (N276D), DM (N460D.N463D), TM1 (N276D.N460D.N463D) and TM4 (S278R.G471S.N460D.N463D).
Fig 2
Fig 2. Detection and epitope mapping of neutralization by germline-reverted forms of VRC01-class bnAbs.
(A) Germline reverted forms of the indicated bnAbs were assayed in TZM-bl cells against Env-pseudotyped viruses 426c, 426c.SM (N276D), 426c.DM (N260D.N463D), 426c.TM1 (N276D.N460D.N463D) and 426c.TM4 (S278R.G471S.N460D.N463D) produced in 293S GnT1- cells. (B) Germline-reverted forms of VRC01, VRC07 and VRC20 were assayed in TZM-bl cells against 426c.TM1 and 426c.TM1.D279K produced in 293S GnT1- cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Vaccination induces HIV broadly neutralizing antibody precursors in humans.
    Leggat DJ, Cohen KW, Willis JR, Fulp WJ, deCamp AC, Kalyuzhniy O, Cottrell CA, Menis S, Finak G, Ballweber-Fleming L, Srikanth A, Plyler JR, Schiffner T, Liguori A, Rahaman F, Lombardo A, Philiponis V, Whaley RE, Seese A, Brand J, Ruppel AM, Hoyland W, Yates NL, Williams LD, Greene K, Gao H, Mahoney CR, Corcoran MM, Cagigi A, Taylor A, Brown DM, Ambrozak DR, Sincomb T, Hu X, Tingle R, Georgeson E, Eskandarzadeh S, Alavi N, Lu D, Mullen TM, Kubitz M, Groschel B, Maenza J, Kolokythas O, Khati N, Bethony J, Crotty S, Roederer M, Karlsson Hedestam GB, Tomaras GD, Montefiori D, Diemert D, Koup RA, Laufer DS, McElrath MJ, McDermott AB, Schief WR. Leggat DJ, et al. Science. 2022 Dec 2;378(6623):eadd6502. doi: 10.1126/science.add6502. Epub 2022 Dec 2. Science. 2022. PMID: 36454825 Free PMC article. Clinical Trial.
  • Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge.
    Felber BK, Lu Z, Hu X, Valentin A, Rosati M, Remmel CAL, Weiner JA, Carpenter MC, Faircloth K, Stanfield-Oakley S, Williams WB, Shen X, Tomaras GD, LaBranche CC, Montefiori D, Trinh HV, Rao M, Alam MS, Vandergrift NA, Saunders KO, Wang Y, Rountree W, Das J, Alter G, Reed SG, Aye PP, Schiro F, Pahar B, Dufour JP, Veazey RS, Marx PA, Venzon DJ, Shaw GM, Ferrari G, Ackerman ME, Haynes BF, Pavlakis GN. Felber BK, et al. Cell Rep. 2020 May 12;31(6):107624. doi: 10.1016/j.celrep.2020.107624. Cell Rep. 2020. PMID: 32402293 Free PMC article.
  • Protein engineering strategies for rational immunogen design.
    Caradonna TM, Schmidt AG. Caradonna TM, et al. NPJ Vaccines. 2021 Dec 17;6(1):154. doi: 10.1038/s41541-021-00417-1. NPJ Vaccines. 2021. PMID: 34921149 Free PMC article. Review.
  • Inducing broad-based immunity against viruses with pandemic potential.
    Sette A, Saphire EO. Sette A, et al. Immunity. 2022 May 10;55(5):738-748. doi: 10.1016/j.immuni.2022.04.010. Immunity. 2022. PMID: 35545026 Free PMC article. Review.
  • Impact of glycan depletion, glycan debranching and increased glycan charge on HIV-1 neutralization sensitivity and immunogenicity.
    D'Addabbo A, Tong T, Crooks ET, Osawa K, Xu J, Thomas A, Allen JD, Crispin M, Binley JM. D'Addabbo A, et al. Glycobiology. 2024 Sep 30;34(11):cwae063. doi: 10.1093/glycob/cwae063. Glycobiology. 2024. PMID: 39115361 Free PMC article.
See all "Cited by" articles

References

    1. McClure MO, Sattentau QJ, Beverley PC, Hearn JP, Fitzgerald AK, Zuckerman AJ, et al. HIV infection of primate lymphocytes and conservation of the CD4 receptor. Nature. 1987;330(6147):487–9. 10.1038/330487a0 . - DOI - PubMed
    1. Bonsignori M, Zhou T, Sheng Z, Chen L, Gao F, Joyce MG, et al. Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell. 2016;165(2):449–63. 10.1016/j.cell.2016.02.022 ; PubMed Central PMCID: PMC4826291. - DOI - PMC - PubMed
    1. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PloS one. 2010;5(1):e8805 10.1371/journal.pone.0008805 ; PubMed Central PMCID: PMC2808385. - DOI - PMC - PubMed
    1. Gristick HB, von Boehmer L, West AP Jr., Schamber M, Gazumyan A, Golijanin J, et al. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nature structural & molecular biology. 2016;23(10):906–15. 10.1038/nsmb.3291 ; PubMed Central PMCID: PMC5127623. - DOI - PMC - PubMed
    1. Huang J, Kang BH, Ishida E, Zhou T, Griesman T, Sheng Z, et al. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity. 2016;45(5):1108–21. 10.1016/j.immuni.2016.10.027 . - DOI - PMC - PubMed

Publication types

MeSH terms